









San Francisco Health Plan Pharmacy & Therapeutics Committee
Wednesday January 27, 2016 7:30AM - 9:30AM
50 Beale St., 12th Floor, San Francisco, CA 94119





Voting Members present:	James Glauber, MD (SFHP Chief Medical Officer) Lisa Ghotbi, Pharm.D. (SFHP Director of Pharmacy) Ron Ruggiero, Pharm.D., OB-Gyn Roger Tiao, Pharm.D. Linda Truong, Pharm.D. Brad Williams, MD Jaime Ruiz, MD (e-vote 01/28/16)
Members Absent	Jamie Ruiz, MD Kathleen Liu, Pharm. D. Ted Li, MD Shawn Houghtaling, Pharm.D. Joseph Pace, MD Lauren Goldman, MD
Others Present:	Olga Mostovetsky, Pharm. D (SFHP Clinical Pharmacist) Dai Tan, Pharm.D (SFHP Pharmacy Resident) Kenneth Garcia, CPhT (SFHP Analyst, Pharmacy Services) Alicia Wong (UCSF Student) Andrew Costiniano, CPhT (SFHP Pharmacy Coordinator) Jenna Heath, Pharm.D. (PerformRx Clinical Pharmacist) William Lam, Pharm.D. (PerformRx Clinical Account Executive) Alan Kaska (Abbott) Jennifer Denning (Bristol Myers Squibb)

TOPICS and DISCUSSIONS	OUTCOME/ ACTION
<p>I. Call to Order & Introductions</p> <p>A) Agenda overview and other topics - (James Glauber) – 2 minutes</p> <p>B) Informational Updates –(James Glauber, Kenneth Garcia) - non-voting item -5 minutes</p> <ul style="list-style-type: none"> • Introduction of new Director of Pharmacy, Lisa Ghotbi • Acute Pain Management online training by Healthcare Concepts (go-live Feb 2016) • Implementation of 90 days supply policy for maintenance brand medications effective 11/1/15 • Auvi-Q and Ventolin recalls • Blood Pressure Utilization 	<p>James Glauber, MD called the meeting to order at 7:32am, introduced Lisa Ghotbi as the new Director of Pharmacy and provided a brief overview of the upcoming on-line acute pain management CME training.</p> <p>James Glauber, MD reviewed the implementation of an online training by Healthcare Concepts for Acute Pain Management. Further details regarding this will be emailed to the committee members.</p> <p>Kenneth Garcia, CPhT discussed:</p> <ul style="list-style-type: none"> • Implementation of the 90 day supply policy for brand medications for select chronic conditions which was implemented to increase access and provider and patient satisfaction. • Auvi-Q nationwide recall: PerformRx has identified 6 SFHP members who have filled Auvi-Q. Aside from PerformRx' network pharmacy faxblast, SFHP also mailed out recall notifications to the 6 impacted members.

<p>C) Review and approval of October 21, 2015 P&T minutes – (James Glauber) – 2 minutes – <u>vote</u></p> <p>D) Adjourn to Closed Session – 60 minutes</p> <ul style="list-style-type: none"> Discussion and Recommendations for changes to SFHP Formulary and Prior Authorization Criteria for select drug classes - 40 minutes - <u>vote</u> <ul style="list-style-type: none"> Urinary Antispasmodics Inhaled Corticosteroids Acne medications Additional Proposed Changes to SFHP Formulary – 5 minutes – <u>vote</u> Closed Session pursuant to Welfare and Institutions Code Section 14087.36 (w) Olga Mostovetsky, PharmD, Clinical Pharmacist, San Francisco Health Plan <p>E) Reconvene in Open Session</p> <p>F) Summary of Closed Session – (James Glauber MD, CMO)-2 minutes –non voting</p> <p>G) Annual SFHP Prior Authorization Criteria Review –(Olga Mostovetsky and Dai Tan)- 40 minutes –<u>vote</u></p> <p>H) Review and approval of Interim Formulary Changes and Formulary Placement for New Drugs to Market –(Olga Mostovetsky and Jenna Marks)-15 minutes-<u>vote</u></p> <p>I) Follow up discussion from July2015 P&T Committee Meeting –(Olga Mostovetsky and Kenneth Garcia) – 5 minutes- non-voting</p> <p>J) Informational Update on New Developments in the Pharmacy Market –(Jenna Marks) -5 minutes- non-voting item</p> <p>K) Adjournment</p> <ul style="list-style-type: none"> Next P&T Committee meeting – 2 minutes <ul style="list-style-type: none"> Wednesday, April 20, 2016 P&T Committee Member Forms 	<ul style="list-style-type: none"> Ventolin HFA lot level recall: based on FDA website, affected lot #s were only distributed to Mississippi and Vermont. Since this is a lot# recall, it is unlikely that SFHP members are affected, so no further action has been taken. Blood Pressure Utilization: covered as pharmacy benefit effective 8/1/15 as discussed in October P&T Meeting. Since implementation through 12/31/2015, there have been 1574 claims for 1574 unique member IDs for BP monitors. <p>Dr. Glauber noted that the utilization for Blood Pressure monitors has been robust.</p>
<p>II. Review and approval of October 21, 2015 P&T minutes P&T Meeting Minutes (James Glauber, MD, CMO) – 2 minutes- vote</p>	<p><u>The committee approved 10/21/2015 P&T minutes.</u> Motion: Brad Williams, MD Second:</p>

 <p>2015_10_21_PT_Minutes_signed</p>	<p>Votes: 7 Approved, 0 Denied, 0 abstained</p> <p>Notes: Alan Kaska and Jennifer Denning left the room at 7:39am due to closed session.</p>
<p>****Adjourn to Closed Session**** Closed Session pursuant to Welfare and Institutions Code Section 14087.36 (w)</p> <p>III. Discussion and Recommendations for Changes to SFHP Formulary and Prior Authorization Criteria for Select Drug Classes (<i>Jenna Marks, PharmD, Regional Clinical Pharmacist, PerformRx and Dai Tan, PharmD, Resident</i>) – 40 minutes – vote</p> <p>A)</p> <p>1. Urinary Antispasmodics</p> <ul style="list-style-type: none"> Proposed Formulary Changes PA Criteria <div style="display: flex; justify-content: space-around; align-items: center;"> <div data-bbox="94 932 293 1050">  <p>Current_Criteria_Urinary_Antispasmodics</p> </div> <div data-bbox="318 932 524 1050">  <p>3.1.02_Proposed Formulary_Changes_</p> </div> </div>	<p>The P&T Committee reviewed and voted on the following items:</p> <p>III.A.1 Urinary Antispasmodics</p> <p>Votes: 7 approved, 0 denied, 0 abstained 1st Motion: Ron Ruggiero, Pharm.D. 2nd Second: Roger Tiao, Pharm.D.</p> <p>Notes: Jenna Heath, PharmD, presented on the antispasmodic agents for urinary incontinence. Topics covered included their place in current clinical guidelines, pharmacology, formulary status, current PA criteria, cost, utilization, PA history, proposed formulary status changes and proposed PA criteria.</p> <p>Clarification was made that the standard step therapy look back period is 180 days.</p> <p>Ron Ruggiero, PharmD stated that he is surprised that Mybetriq is not requested more given the advertisements on TV. Per Jenna Heath, PharmD, this may be due national guidelines not recommending Mybetriq over the older agents.</p> <p>Toviaz was originally proposed to have Step Therapy but due to recent pricing changes, recommendation was made to keep Toviaz non-formulary.</p> <p>Approved changes can be found at the following locations:</p> <p style="padding-left: 40px;">Formulary changes: under “Materials” section at http://www.sfhp.org/providers/formulary/pharmacy-therapeutics-committee/</p> <p style="padding-left: 40px;">PA criteria: http://www.sfhp.org/files/providers/formulary/Prior_Auth_Criteria.pdf</p>
<p>2. Inhaled Corticosteroids</p> <ul style="list-style-type: none"> Proposed Formulary Changes 	<p>III.A.2 Inhaled Corticosteroids</p>

<ul style="list-style-type: none"> PA Criteria <div>  Monograph_Inhaled_steroids  CurrentCriteria_Respiratory_Asthma_COPD  CurrentCriteria_Respiratory_Asthma_CS </div> <div>  Proposed_Criteria_Respiratory_Corticosteroids  3.2_02_ProposedFormulary_Changes_ </div>	<p>Votes: 7 approved, 0 denied, 0 abstained 1st Motion: Roger Tiao, Pharm.D. 2nd Second:</p> <p>Notes: Jenna Heath, PharmD, presented the Inhaled Corticosteroid agents. Topics covered included their place in current clinical guidelines, pharmacology, formulary status, current PA criteria, cost, utilization, PA history, proposed formulary status changes and proposed PA criteria.</p> <p>Ron Ruggiero, Pharm.D. asked if once a day dosed medications cost more than twice a day dosed medications. Per Jenna, the difference is not substantial and the once daily agents are lower compared to some formulations.</p> <p>Jenna Heath, PharmD discussed indicated treatments by age group. Advair requires a PA except for children 4-12 years of age. For children aged 13 who have been getting Advair in the past, there is currently no self-grandfathering in place to allow them to continue treatment with Advair. A prior authorization would have to be submitted if continuation of treatment with Advair is needed. This would be discussed further with PerformRx offline per Dr. James Glauber, MD.</p> <p>Olga Mostovetsky recommended that we increase the quantity limit for Asmanex HFA and other inhaled corticosteroids to 2 units per month rather than the recommended 1 unit per month. James Glauber, MD concurred, commenting that it is common for patients to increase their dosage during an exacerbation or cold, so it would be reasonable to allow more than 1 unit per month.</p> <p>Approved changes can be found at the following locations:</p> <p>Formulary changes: under "Materials" section at http://www.sfhp.org/providers/formulary/pharmacy-therapeutics-committee/</p> <p>PA criteria: http://www.sfhp.org/files/providers/formulary/Prior_Auth_Criteria.pdf</p>
<p>3. Acne Medications</p> <ul style="list-style-type: none"> Proposed Formulary Changes PA Criteria 	<p>III.A.3 Acne Medications</p> <p>Votes: 7 approved, 0 denied, 0 abstained 1st Motion: Dr. Ron Ruggiero, Pharm.D. 2nd Second:</p>

 ClassReview_Monograph_Acne_Rosacea
 Proposed_Formulary_Change_AcneProducts
 Current_Criteria_Acne_Medications
 Proposed_Criteria_Acne_Medications

Notes: Jenna Heath, PharmD, presented the acne agents. Topics covered included place in therapy, clinical guidelines, pharmacology, formulary status, current PA criteria, cost, utilization, PA history, proposed formulary status changes and proposed PA criteria.

Concerning current drug pregnancy risk factor ratings, per Ron Ruggiero, PharmD there will be new labeling laws coming into effect to replace the current system.

Brad Williams, MD asked if Clindamycin/Benzoyl Peroxide combination products are relatively inexpensive. Per Dr. Jenna, Marks, MD, the combination products are significantly more expensive than using single ingredient products.

Approved changes can be found at the following locations:

Formulary changes: under "Materials" section at <http://www.sfhp.org/providers/formulary/pharmacy-therapeutics-committee/>

PA criteria: http://www.sfhp.org/files/providers/formulary/Prior_Auth_Criteria.pdf

B) Additional Proposed Changes to SFHP Formulary
 (Olga Mostovetsky, PharmD, Clinical Pharmacist)- 5 minutes – **vote**


 4.00.01_Proposed Formulary_Changes_

The P&T Committee reviewed and voted on the following items:

III.B. Additional Proposed Changes to SFHP Formulary

Votes: 7 approved, 0 denied, 0 abstained

1st Motion: Dr. Brad Williams, MD

2nd Second:

Notes: Olga Mostovetsky, Pharm D discussed additional proposed changes to the SFHP formularies. Discussions covered proposed changes for over 10 individual medications (e.g. making memantine immediate release formulary preferred (Tier 1))..

James Glauber, MD inquired if SFHP has received any prior authorization requests for PCSK9 inhibitors. Dr. Olga Mostovetsky, PharmD, responded that there has been no requests were submitted.

Approved changes can be found under "Materials"

	<p>section at http://www.sfhp.org/providers/formulary/pharmacy-therapeutics-committee/</p>
****RECONVENE IN OPEN SESSION****	Reconvened to open session around 8:30am.
IV. Summary of Closed Session – 2 minutes (James Glauber MD, CMO)-2 minutes –non voting	<u>Non-Voting item</u> Dr. Ron Ruggiero, Pharm.D. left the room around 8:30am.
V. Annual SFHP Prior Authorization Criteria Review (Olga Mostovetsky PharmD, Clinical Pharmacist and Dai Tan, Pharm.D. Pharmacy Resident)- 40 minutes – <u>vote</u> <div data-bbox="256 795 323 856" data-label="Image"> </div> <div data-bbox="186 856 389 911" data-label="Text"> <p>6.1_SFHP_Prior_Auth_CriteriaV3.pdf</p> </div>	<u>The P&T Committee reviewed and voted on the following changes:</u> <u>Votes:</u> 7 approved, 0 denied, 0 abstained <u>1st Motion:</u> Dr. Ruggiero, PharmD <u>2nd Second:</u> <u>Notes:</u> Olga Mostovetsky, PharmD discussed the annual formulary review process conducted by SFHP in preparation for January P&T. Discussion covered proposed changes for over 30 prior authorization criteria . Ron Ruggiero, Pharm.D. returned at 8:41am (5 minutes into presentation). Olga Mostovetsky, PharmD discussed additional PA criteria updates for several drug classes that were not included in pre-P&T packets (examples include 2 nd generation antihistamines, colchicine and enteral nutrition products). Dai Tan, PharmD discussed new criteria developed by SFHP as part of the annual PA criteria review process. <u>Short-Acting Opiates:</u> James Glauber, MD asked the committee for feedback on duration of approval for short-acting opiates for acute pain. Per Dr. Ruggiero, there has been news regarding high school students from Ohio becoming addicted to opiates and moving onto illicit substances such as heroin after being treated with short acting opiates for sports-related injuries. James Glauber, MD suggested updating the PA criteria to limit the approval period for short-acting opiates for acute pain from 1 year to 3 months. <u>Onychomycosis agents:</u> Dai Tan, Pharm.D. discussed new criteria for onychomycosis agents including the requirement for culture or KOH test positive for fungal infection. James Glauber, MD asked. Brad Williams, MD for feedback on the testing requirement. Per Dr.

Williams, he does not employ these tests and treats empirically and relates that empiric treatment is the common standard of care. James Glauber, MD requested removal of the requirement for culture or KOH test positive for fungal infection.

Brad Williams, MD inquired about the efficacy of Jublia and if the newer agents are comparable to Penlac. Dr. Dai Tan, Pharm.D., the cure rate for newer topical agents is relatively low (10-15%), and similar to Penlac.

Viibryd:

Linda Truong, PharmD asked whether a 2-3 month trial period is required for all three preferred agents combined or each preferred agent prior to approval of Viibryd. She emphasized that SSRIs take at least 6-8 weeks to work. SFHP clarified that a 2-3 month trial of each of the three preferred medications is required.

Approved changes can be found at the following locations:

List of updated PA criteria: "Materials" section at

<http://www.sfhp.org/providers/formulary/pharmacy-therapeutics-committee/>


PA criteria:

http://www.sfhp.org/files/providers/formulary/Prior_Auth_Criteria.pdf

VI. Review and Approval of Interim Formulary Changes and PA criteria and Formulary Placement for New Drugs to Market

(Olga Mostovetsky PharmD, Clinical Pharmacist and Jenna Heath PharmD, Clinical Pharmacist)-15 minutes-
vote

A) Interim Formulary Changes



B) New Drugs to Market

The P&T Committee reviewed and voted on the following items:

Votes: 7 approved, 0 denied, 0 abstained

1st Motion: Dr. Roger Tiao, Pharm.D.

2nd Second:

Notes: Olga Mostovetsky, PharmD discussed interim formulary changes that took place prior to January P&T committee meeting which included adding Suprax capsule to formulary and monthly review and formulary placement for new drugs to market and formulary changes needed as a result of drug discontinuations.

Jenna Marks, PharmD, highlighted most notable drugs introduced to market since the last meeting.

Approved changes can be found under "Materials" section

at <http://www.sfhp.org/providers/formulary/pharm>

	<p>including Praxbind (Idarucizumab) approval for the reversal of the novel oral anti-coagulant Pradaxa and HCV treatment. Question was raised whether Praxbind should be on pharmacy formulary. This will be researched further and discussed at April 2016 meeting.</p> <p>Linda Truong, PharmD mentioned that there is an Andexanet alfa agent underway for the reversal of Xarelto and other direct Factor Xa inhibitors.</p>
<p>IX. Adjournment</p> <ul style="list-style-type: none"> Next P&T Committee meeting – 2 minutes <ul style="list-style-type: none"> Wednesday, April 20, 2016 P&T Committee Member Forms 	<p><u>Non-Voting item</u> Meeting adjourned at 9:25 am</p> <p><u>Notes:</u> Olga Mostovetsky, PharmD reminded the committee that the next meeting is on April 20th 2016 and that yearly forms are due to be submitted.</p>

The meeting was adjourned at **9:25 AM**

Respectfully submitted by:



James Glauber, MD, MPH
SFHP Chief Medical Officer

02/05/16

Date